CAR-T for R/R B-NHL
This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for at least 2 years.
Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|CAR - T CD19/CD20/CD22/CD30
BIOLOGICAL: CAR-T
Overall Response Rate, Rate of complete remission and patial remission, One months after CAR-T cells were infused
Adverse toxicity, Accordingto CTCAE 4.0 criteria, Day 0, day 4, week 1, week 3, week 4, month 2, month 24 after CAR-T cells were infused|CAR-T cell survival, the survival of CAR-T cells detected in patients' peripheral blood, every week in first 4 weeks after CAR-T cells infusion, then every 3 months for 2 years, then every 6 months for next 2 years
This study is a single arm study to investigate the efficacy and safety of CAR-T targeted CD19/CD20/CD22/CD30 in relapse and refractory non-Hodgkin lymphoma patients. Ten patients will recruieted, admitted in hospital for 1 month for the CAR-T treatment and follow-up for at least 2 years.